A moisturizing composition for delivery of lidocaine is provided with viscosity thickening provided by the use of sclerotium gum and hydroxyethylcellulose in approximately equivalent amounts in a slightly acidic vehicle without anionic compounds.

A moisturizing composition for delivery of lidocaine is provided with viscosity thickening provided by the use of sclerotium gum and hydroxyethylcellulose in approximately equivalent amounts in a slightly acidic vehicle without anionic compounds.

The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas.

##STR00001## wherein A is —(CH2).sub.a—CH═CH—(CH 2).sub.5-a—H where a is from 0 to 5, —(CH2).sub.b—CH═CH—(CH 2).sub.6-b—H where b is from 0 to 6, —(CH2).sub.c—CH═CH—(CH 2).sub.7-c—H where c is from 0 to 7, —(CH2).sub.d—CH═CH—(CH 2).sub.8-d—H where d is from 0 to 8, or —CH2).sub.e—CH═CH—(CH 2).sub.9-d—H where d is from 0 to 9; B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

The present disclosure relates to a stabilized or more stable volatile compound, e.g., menthol, compositions and methods of making and using them including a mixture of a stabilizer compound of formula (I), for example, undecylenic acid methyl ester, undecylenic acid or a salt thereof and a volatile compound where the volatile compound is less susceptible to volatizing into a gas.

##STR00001## wherein A is —(CH2).sub.a—CH═CH—(CH 2).sub.5-a—H where a is from 0 to 5, —(CH2).sub.b—CH═CH—(CH 2).sub.6-b—H where b is from 0 to 6, —(CH2).sub.c—CH═CH—(CH 2).sub.7-c—H where c is from 0 to 7, —(CH2).sub.d—CH═CH—(CH 2).sub.8-d—H where d is from 0 to 8, or —CH2).sub.e—CH═CH—(CH 2).sub.9-d—H where d is from 0 to 9; B is hydrogen or C.sub.1-5 alkyl; and pharmaceutically acceptable salts thereof where B is hydrogen.

Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that contain a therapeutic STAT3-targeting inhibitory RNA. Also provided are methods of using such compositions to treat a patient having fibrosis or a disease associated with fibrosis.

Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that contain a therapeutic STAT3-targeting inhibitory RNA. Also provided are methods of using such compositions to treat a patient having fibrosis or a disease associated with fibrosis.

The invention relates to a medicinal composition for treating a cold, a preparation method and application thereof. The cold medication composition is made from aloe vera soap, an isopropyl alcohol solution, sea salt, distilled water, and natural gum resin. The invention also relates to a preparation method of the composition and the application of the composition for treating the cold.

The invention relates to a medicinal composition for treating a cold, a preparation method and application thereof. The cold medication composition is made from aloe vera soap, an isopropyl alcohol solution, sea salt, distilled water, and natural gum resin. The invention also relates to a preparation method of the composition and the application of the composition for treating the cold.

The invention relates to a medicinal composition for treating a cold, a preparation method and application thereof. The cold medication composition is made from aloe vera soap, an isopropyl alcohol solution, sea salt, distilled water, and natural gum resin. The invention also relates to a preparation method of the composition and the application of the composition for treating the cold.

Methods of preventing or treating Parkinson's disease in subjects are described where drugs are administered to subjects in effective amounts to cause the farnesylation of PARIS and the enhanced expression of PGC-1α in the brain. These methods alleviate the effects of Parkinson's disease in subjects, in part, by preventing the loss of dopamine neurons.